Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marta Dueñas Porto
Observed names:
M. Duenas Porto,
M. Duenas-Porto,
Marta Duenas Porto,
Marta Duenas-Porto,
Marta Dueñas
Institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre,
Centro de Investigación Biomédica en Red,
Centro de Investigación Biomédica en Red de Cáncer,
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
Observed institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre,
Centro de Investigación Biomédica en Red,
Centro de Investigación Biomédica en Red de Cáncer,
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
ORCID:
0000-0003-0857-9726
Observed ORCID:
0000-0003-0857-9726
OpenAlex ID:
A5063969801
Works
9
Awards
1
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
2022
·
Julie Earl
, Silvia Calabuig-Fariñas
, et al.
·
Journal of Visualized Experiments
·
6
RB-independent activity of Cdk4/6 in bladder cancer.
2016
·
Daniel E. Castellano
, Carolina Rubio
, et al.
·
Journal of Clinical Oncology
·
4
Ip14-31 Bladimirplus: a Non-invasive Urine-based Biomarker Panel for Predicting Bladder Cancer Immunotherapy Outcomes
2025
·
Félix Guerrero-Ramos
, Cristian Suárez-Cabrera
, et al.
·
The Journal of Urology
·
3
PDF
Circulating Free miRNAs as Liquid Biopsy Biomarkers for Early Detection of Breast Cancer in Peruvian Women
2026
·
Diana Arenas Machaca
, Álvaro Martín de Bernardo
, et al.
·
Cancers
·
1
Application of LEGENDplex™ Multiplex Immunoassays for Immune Profiling and Toxicity Monitoring in Urothelial Cancer
2026
·
Esther Montesinos
, Julia del Prado Montero
, et al.
·
The Journal of Liquid Biopsy
PDF
Baseline intratumoral TCRβ and TCRγ repertoires predict response to immune checkpoint inhibitors in advanced renal cell carcinoma
2026
·
Manuel Pino-González
, Martín Lázaro-Quintela
, et al.
·
medRxiv
PDF
A0583 – BlaDimiRplus: A multimodal, non-invasive urine-based tool for predicting immunotherapy response in bladder cancer
2025
·
F. Guerrero-Ramos
, C. Suárez-Cabrera
, et al.
·
European Urology
A0794 – High risk NMIBC treated with atezolizumab and BCG: BladderGATE clinical trial (NCT04134000) analysis finds recurrence-associated biomarkers
2025
·
C. Gomez Del Cañizo
, V.M. García Martínez
, et al.
·
European Urology
PIK3CA gene alterations in bladder cancer: Analysis of correlative series of transurethral resection (TUR)—Correlation with grade histology and tumor size.
2012
·
Daniel E. Castellano
, Juan Sepulveda
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
9
Citation count:
14
H-index:
3
I10-index:
Year
Topic
Type